Tags: oncology, m-and-a, novartis, breast-cancer

Novartis Pays Up to $3B for Synnovation's PI3Kα Inhibitor — A Bet on Its Own Breast Cancer Franchise

By FieldPulse Editorial · March 22, 2026

Novartis is acquiring Synnovation Therapeutics for $2B upfront and up to $3B total to gain SNV4818, a next-generation PI3Kα inhibitor in Phase 1/2 for HR+/HER2- breast cancer — a direct upgrade on its own approved drug Piqray.

Novartis announced on March 19-20, 2026 it will acquire the Pikavation Therapeutics business unit of Synnovation Therapeutics in a deal valued at $2 billion upfront with up to $1 billion in additional milestone payments.

The asset is SNV4818, a pan-mutant selective PI3Kα inhibitor currently in Phase 1/2 development for HR+/HER2- metastatic breast cancer.

The acquisition is notable for what it signals internally: Novartis already sells Piqray (alpelisib), an approved PI3Kα inhibitor for the same indication.

SNV4818 is designed as a direct successor with a meaningfully better side-effect profile.

The key difference is selectivity — SNV4818 targets only mutated PI3Kα, sparing wild-type PI3Kα in healthy pancreatic cells.

Piqray's main limitation in the field has been its hyperglycemia profile, which restricts use in patients with diabetes or pre-diabetes and creates significant management burden.

Approximately 40% of HR+/HER2- metastatic breast cancer patients carry PIK3CA mutations — the population both drugs are designed to serve.

The deal is expected to close in the first half of 2026.

This is the second significant oncology M&A deal announced the same week.

Collegium Pharmaceutical separately acquired Azstarys (serdexmethylphenidate) from Corium Therapeutics, adding an ADHD product to its specialty CNS portfolio.

What it means for reps: Novartis oncology reps selling Piqray should expect the internal transition conversation to start early.

When SNV4818 reaches market — assuming successful Phase 3 development — it will likely cannibalize Piqray while defending territory against Lilly's Verzenio (abemaciclib) and AstraZeneca's Truqap (capivasertib), the other PI3K-pathway agent approved in this space.

AstraZeneca and Pfizer oncology reps should begin building competitive dossiers on SNV4818 now.